Journal of Clinical Oncology
Articles in this Issue
Long-term oncological outcomes of prostate cancer upgrading following robot-assisted radical prostatectomy.
351 Background: Pathologic upgrading from biopsy to final pathology at the time of Robot-Assisted Radical Prostatectomy (R...
Determinants of treatment intensification in metastatic hormone-sensitive prostate cancer: Institutional vs patient-level factors in a diverse UK multicentre cohort.
40 Background: In the United States, racial disparities in the use of treatment intensification (TI) for metastatic hormon...
Chromophobe renal cell carcinoma: Long-term survival and treatment patterns from a real-world cohort.
467 Background: Chromophobe renal cell carcinoma (chRCC) is an uncommon subtype of renal cell carcinoma (RCC), representin...
Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab (Pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from phase 2 2870-002/SKB264-II-06 study.
744 Background: There are limited 1L therapy options for cisplatin-ineligible patients with locally advanced or metastatic...
Spatially mapping the prostate cancer tumor microenvironment to reveal immune cell drivers of aggressive disease.
400 Background: Cells of the tumor microenvironment (TME) have been implicated in prostate cancer (PCa) progression. Howev...
Clinical outcomes of metastatic urothelial carcinoma patients discontinuing enfortumab vedotin due to toxicity and/or clinical response.
719 Background: Enfortumab vedotin (EV) monotherapy and its combination with pembrolizumab (EV/P) are established treatmen...
Impact of abiraterone versus enzalutamide on depression and anxiety in hormone-sensitive prostate cancer (HSPC).
147 Background: Abiraterone (A) and enzalutamide (E) are now standard of care options for localized high risk and metastat...
Homologous recombination repair gene alterations and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
829 Background: Enfortumab vedotin plus pembrolizumab (EV-P) represents the standard of care first-line therapy for patien...
Biomarker analysis of neoadjuvant atezolizumab in upper-tract urothelial carcinoma: Results from the ABACUS-2 trial.
832 Background: High-risk upper-tract urothelial carcinoma (UTUC) is associated with poor clinical outcomes and there are...
Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC).
LBA639 Background: PPARG is a master regulator of luminal lineage in UC with two-thirds of adv tumors classified as lumina...
The impact of rising PSA during salvage radiotherapy post radical prostatectomy on relapse.
365 Background: Salvage radiotherapy (RT) is an effective curative salvage of relapse after radical prostatectomy (RP). CA...
Multidimensional profiling of clinical trial cohorts and the characterization of radiotherapy/immunotherapy response biology in localised and metastatic muscle-invasive bladder cancer.
824 Background: Whilst combined radiotherapy/immunotherapy shows promising clinical potential, biological determinants of...
Prognostic utility of neutrophil:lymphocyte ratio (NLR) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration resistant prostate cancer (mCRPC).
207 Background: LuPSMA has a proven clinical benefit in mCRPC, but there is a need to develop predictive and prognostic bi...
SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.
622 Background: Clinical stage I (CSI) testicular germ cell neoplasms (tGCN) represent the most frequent disease presentat...
Prostate cancer: Correlating the clinical phenotype to the genotype.
376 Background: Prostate cancer (PC) is the most common malignant tumor for men in Israel. There are known inherited patho...
Long-term clinical outcomes and genomic predictors of PSMA-PET/CT-guided cytoreductive progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
190 Background: The long-term effect of cytoreductive progression-directed therapy (PDT) based on prostate-specific membra...
V-set immunoregulatory receptor as a novel molecular target for genitourinary cancers.
515 Background: Immune checkpoint inhibitors (ICI) target immune receptors on the cell surface of T lymphocytes to enhance...
Comparison of clinicopathological features and prognoses of de-novo metastatic male and female bladder cancer patients.
867 Background: Bladder cancer is a common urological malignancy, but de novo metastatic disease at presentation is relati...
Efficacy, safety, and cost-effectiveness of reduced vs. full initial dose androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer: A multicenter retrospective study.
371 Background: The introduction of novel androgen receptor signaling inhibitors (ARSIs) has significantly transformed the...
Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin ± pembrolizumab: A single-cell spatial transcriptomic analysis.
818 Background: The current treatment landscape of metastatic urothelial cancer has recently expanded beyond platinum-base...
Implementation of patient reported outcomes as nonmuscle-invasive bladder cancer clinical trial endpoints.
722 Background: Nonmuscle-invasive bladder cancer (NMIBC) represents a highly recurrent malignancy requiring repeated tran...
Progression after first-line chemotherapy with normal serum tumor markers (STM) in non-seminomatous germ-cell tumors (NSGCT).
615 Background: Surveillance of patients with NSGCT following first-line chemotherapy typically relies on a combination of...
Evaluation of quality of life endpoint planning and reporting in phase III genitourinary oncology randomized controlled trials.
720 Background: Quality-of-life (QoL) endpoints are vital for assessing patient-centered outcomes in genitourinary (GU) ca...
<i>MTAP</i> loss in penile squamous cell carcinoma (penSCC): A genomic landscape study.
11 Background: Clinically advanced penSCC is a highly aggressive malignancy with poor prognosis, and thus further explorat...
Prognostic value and clinical utility of a six-gene signature for aggressive prostate cancer among clinically low or intermediate risk patients.
381 Background: Prostate cancer (PCa) is diagnosed in approximately 1.5 million men worldwide each year. Many men have cli...